Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In Myelodysplastic syndrome, epigenetic treatments such as Azacitidine and Decitabine have been highlighted in phase 3 studies. However, as the 1st line treatment, it has not been evaluated the head to head comparison of two drugs. This study is a retrospective study to compare the efficacy of two drugs.
Among 300 MDS patient, 200 of them have been taking Azacitidine and 100 of them have been taking Decitabine. Medical chart of these patients will be reviewed to assess the efficacy and safety between two agents.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Azacitidine | 200 MDS patients taking Azacitidine will be assessed | ||
| Decitabine | 100 MDS patients taking Decitabine will be assessed |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Response rate | Compare Azacitidine and Decitabine's treatment response rate in MDS patients | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy | To compare hematologic improvement between Azacitidine and decitabine | 6 months |
| Survival rate | To compare survival rate between Azacitidine and decitabine |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
MDS patients who are diagnosed at SNUH
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SNUH | Seoul | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23432512 | Derived | Lee YG, Kim I, Yoon SS, Park S, Cheong JW, Min YH, Lee JO, Bang SM, Yi HG, Kim CS, Park Y, Kim BS, Mun YC, Seong CM, Park J, Lee JH, Kim SY, Lee HG, Kim YK, Kim HJ; Korean Society of Haematology AML/MDS working party. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol. 2013 May;161(3):339-47. doi: 10.1111/bjh.12256. Epub 2013 Feb 21. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009190 | Myelodysplastic Syndromes |
| ID | Term |
|---|---|
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 months |
| Number of participants with non-hematologic toxicities | To compare toxicity between Azacitidine and decitabine | 6 months |
| infection rate | To compare infection rate between Azacitidine and decitabine | 6 months |